Emcure Pharmaceuticals Ltd. (BSE: 544210, NSE: EMCURE) has reported a robust start to FY26, with its consolidated revenue for Q1 reaching ₹2,101 crore, a 15.7% year-on-year (YoY) growth, and profit after tax (PAT) rising by 41% YoY to ₹215 crore. The strong quarterly performance was driven by solid growth across both domestic and international markets.
The company’s EBITDA grew by 20.1% YoY to ₹404 crore, with EBITDA margins improving to 19.2%. Emcure’s international business remained a key growth driver, clocking ₹1,106 crore in sales, up 22.1% YoY, led by strong performances in the Rest of the World (up 41.9%), Canada (up 16.4%), and Europe (up 12.8%).
On the domestic front, revenues reached ₹995 crore, registering a 9.4% YoY growth, aided by continued momentum across key therapeutic areas and new initiatives in dermatology and OTC segments. The company also strengthened its portfolio through an expanded partnership with Sanofi, which now includes the Oral Anti-diabetic portfolio in addition to the cardiovascular segment.
Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said:
“We delivered robust performance across all businesses in Q1. We continue to augment our portfolio in all our focus markets though in-licensing and in-house development. The expanded Sanofi partnership positions us well in the fast-growing metabolic segment. We also have a strong product pipeline for both our domestic and international markets which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins.”
Key Financial Highlights – Q1 FY26 (Consolidated):
-
Revenue from operations: ₹2,101 crore vs ₹1,815 crore (↑15.7% YoY)
-
EBITDA: ₹404 crore vs ₹336 crore (↑20.1% YoY); margin at 19.2%
-
PAT: ₹215 crore vs ₹153 crore (↑41% YoY); PAT margin at 10.2%
-
Domestic revenue: ₹995 crore (↑9.4% YoY)
-
International revenue: ₹1,106 crore (↑22.1% YoY)
Emcure continues to prioritize R&D and portfolio expansion to drive long-term growth across geographies. With presence in over 70 countries, including strong markets in Europe and Canada, the company is well-positioned to leverage future opportunities in both regulated and emerging markets.
